Several databases have been published to predict alternative splicing of mRNAs by analysing the exon linkage relationship by alignment of expressed sequence tags (ESTs) to the genome sequence; however, little effort has been made to investigate the relationship between cancers and alternative splicing. We developed a program, Alternative Splicing Assembler (ASA), to look for splicing variants of human gene transcripts by genome-wide ESTs alignment. Using ASA, we constructed the biosino alternative splicing database (BASD), which predicted splicing variants for reference sequences from the reference sequence database (RefSeq) and presented them in both graph and text formats. EST clusters that differ from the reference sequences in at least one splicing site were counted as splicing variants. Of 4322 genes screened, 3490 (81%) were observed with at least one alternative splicing variants. To discover the variants associated with cancers, tissue sources of EST sequences were extracted from the UniLib database and ESTs from the same tissue type were counted. These were regarded as the indicators for gene expression level. Using Fisher's exact test, alternative splicing variants, of which EST counts were significantly different between cancer tissues and their counterpart normal tissues, were identified. It was predicted that 2149 variants, or 383 variants after Bonferroni correction, of 26 812 variants were likely tumor-associated. By reverse transcription-PCR, 11 of 13 novel alternative splicing variants and eight of nine variants' tissue specificity were confirmed in hepatocelluar carcinoma and in lung cancer. The possible involvement of alternative splicing in cancer is discussed.
Introduction
One of the remarkable revelations that the recent description and annotation of the human genome from the International Human Genome Sequencing Consortium and private company Celera Genomics has brought us is the prediction that there are about 30 000-40 000 gene transcripts in human beings (Lander et al., 2001; Venter et al., 2001) , although only 60% of these genes were consistent in different data sources (Hogenesch et al., 2001) . Discussions about the almost inestimable complex function produced by those limited number of genes were focused on transcription regulation and alternative splicing (Black, 2000; Claverie, 2001) , in addition to post-translation modification, such as phosphoration and glycosylation, which presumably contributes to the diversified functions of proteins. Alternative splicing is an important mechanism in higher eukaryotes for producing proteomic complexity, since approximately 30-65% genes are alternatively spliced as estimated by genomically aligned expressed sequence tags (ESTs) (Mironov et al., 1999; Brett et al., 2000; Kan et al., 2002) . Combining these mechanisms, the human organism could conceivably produce hundreds of thousands of different proteins by the estimated 35 000 human genes.
Alternative splicing of pre-mRNA is a versatile mechanism for regulating gene function at the posttranscription level. As many as 15% of single base-pair mutations that cause human genetic diseases result in alternative splicing defects as indicated by a survey of mutations in splicing junctions (Krawzczak et al., 1992) . The differential expression of alternative spliced genes in cancer tissue has been well documented. For example, Bcl-x, a member of the Bcl-2 family of apoptosis regulators, has two alternative isoforms, Bcl-xL and Bcl-xS, resulting from 5 0 splicing of exon 2. Only BclxL, believed to play a major role in carcinogenesis, is overexpressed in small cell lung carcinoma (Reeve et al., 1996) and in 60% of invasive breast carcinomas (Olopade et al., 1997) . Another example is CD44, which is a membrane glycoprotein consisting of nine variable exons. Elevated expression of CD44 variants containing variable exon 6 in solid tumor tissue and the soluble variant in serum might be applied as a probable diagnostic marker for bladder cancer (Goodison et al., 1999) .
Alignment of ESTs to the genome is a potentially powerful means to predict alternative splicing of gene transcripts. Wolfsberg and Landsman (1997) demonstrated that alternative mRNA formats could be discovered through the assembly of ESTs derived from the gene . Mironov et al. (1999) have also studied alternative splicing of human genes by using EST contigs from the TIGR Human Gene Index . Recently, a software tool, Transcript Assembly Program (TAP), which deduces the gene structure by genomic EST alignments, was developed (Kan et al., 2001; Kan et al., 2002) . Databases for alternatively spliced mRNAs including AsMamDB, HASDB, PALS and SpliceNest, all of which are based on UniGene clusters, have been constructed Modrek et al., 2001; Coward et al., 2002; Huang et al., 2002) . The EST database would give detailed information of cDNA libraries and make it possible to predict tissue expression. For example, BodyMap was established to acquire tissue distribution data through collection of site-directed 3 0 ESTs (Kawamoto et al., 2000) . Xu et al. (2002) developed an automated method for discovering tissue-specific regulation through a genome-wide analysis of ESTs . Since about 45% of the human EST sequences are derived from cancer cells, it would be possible to identify cancer-associated mRNA variants by counting the number of ESTs from the cancer and its counterpart normal tissue libraries (Scheurle et al., 2000; Baranova et al., 2001; Xie et al., 2002; Wang et al., 2003) .
We hereby developed the Alternative Splicing Assembler (ASA) program, which searched all putative alternative splicing variants through genomic EST alignment. Using this program, a human alternative splicing database was constructed based on curated reference sequence database (RefSeq). Splicing variants related to cancer tissues were identified. A total of 26 812 alternatively spliced variants from 4322 genes were included in the database, in which 2149 variants from 1827 genes were predicted as cancer associated. A total of 13 novel splicing variants and nine cancer-related variants were further tested by reverse transcription (RT)-PCR in clinical samples.
Results

ASA was created to identify alternative splicing of human gene transcripts
The first public version of our program, ASA, was freely available at biosino alternative splicing database (BASD). A brief help file is also provided at the download page. The current version has been successfully tested in the IRIX 6.5 system.
We randomly selected 52 genes from alternative splicing database (ASDB) (Dralyuk et al., 2000) , all having previously reported alternative splicing isoforms. Reference sequences for these genes were selected from the RefSeq database and used for alternative splicing searching by ASA. Alternative splicing variants were observed in 46 out of 52 genes as reported (Table 1) . Further study suggested that the reason why no splicing variant was detected by ASA in the remaining six genes was probably because only a few ESTs were available for these genes. Only four EST hits were available on the average for these six genes, while 202 EST hits could be found for the other 46 genes. The limited number of ESTs did not cover the splicing sites present in the ASDB. Based on this sample, the ASA gives a false negative result of 12%, or, it might correctly report about 88% of alternatively spliced genes. In this aspect, ASA is comparable with SpliceNest, PALS and HASDB databases, which have false negative rates of 15, 35, and 38%, respectively (Table 1) .
EST sequences might be contaminated by genomic sequences, vector sequences and chimaeric cDNA clones. The contamination along with sequencing errors may cause mistakes in EST assembly and give false splicing variants. In order to test the effect of these factors, we randomly selected 82 splicing variants from 67 genes and compared these variants with the nonredundant database of GenBank. Approximately 26% (21 out of 82) variants found at least one reported mRNA sequence that is homologous to the query sequence in the nonredundant database (Table 2) . Since mRNA sequences deposited into the nonredundant database came from different labs, the existence of these variants would be highly reliable. We further selected 13 variants, three with homolog sequences in nonredundant database and 10 with only homolog ESTs (Table 2) , and performed RT-PCR to test their presence in clinical samples of hepatocelluar carcinoma and lung cancer. In total, 11 of 13 (85%) variants were confirmed by RT-PCR and sequencing. Among these 13 variants, eight variants were supported only by one EST and six of the eight were confirmed.
Analysis of the alternatively spliced variants and their tissue distribution in BASD BASD presents possible splicing variants of gene transcripts in both text and graph forms. Bar-link graphs show the distribution of exons along the chromosomes (Figure 1 ). The 5 0 or 3 0 end extension of a splicing variant is indicated. Although the 5 0 /3 0 extensions were not confirmed by other experiments, they might provide some additional useful information to the full-length cDNA projects. A total of 4322 reference sequences were screened and 3490 (81%) reference sequences were predicted as alternatively spliced, producing 26 812 splicing variants. On average, six splicing variants were observed for each reference sequence. The distribution of EST counts was graphed to scale representing percentage of variants ( Figure 2 ). In all, 87% variants contained less than 16 ESTs, and 58% were represented by the EST singletons. If the singletons were excluded from the database, then only 66% genes were alternatively spliced, which is consistent with previous reports (Mironov et al., 1999; Brett et al., 2000; Kan et al., 2002) . Although the magnitude of the overestimate has not been assessed, the actual number of variants may be certainly smaller due to raw DNA sequencing errors and contaminated ESTs derived from non-native splicing. In addition, EST clusters, homologous to another reference sequence and not overlapping each other, might be counted as two independent variants (Figure 1 ), whereas these EST clusters could represent different regions of the same mRNA isoform.
In order to analyse the tissue specificity of the splicing variants, we took the source information from cDNA libraries in the National Center for Biotechnology Information (NCBI) EST database. Library tissue sources were extracted from this database and verified manually. A total of 6593 libraries were left and classified into 293 tissue types. A sample of 127 random genes was used to analyse the tissue distribution of alternative splicing (Table 3 ). There were on average four variants for each gene in the brain and three variants in the liver that ranks the top two, whereas that number was 1.8 in all these 17 tissue types analysed. This observation was consistent with a previous report that the brain and liver were tissue types with enriched alternative splicing (Stamm et al., 2000) ; however, more 
EST information may help identify additional splicing variants. Interestingly, about 56% splicing variants were found in only one tissue type. Considering that six splicing variants were observed per gene, it would be expected that a large fraction of splicing variants are tissue specific.
Identification of cancer-associated splicing variants
Splicing variants were classified according to their cancer or normal tissue sources. By simply counting ESTs, we found that about 35% splicing variants were detected exclusively in cancer tissues, for example no EST representing this splicing variant was identified in normal tissues, and 29% were only detected in normal tissues (Table 3 ). This implies that new splicing variants might be generated during carcinogenesis. This result supports the observation that during carcinogenesis not only is the expression profile affected but the splicing pattern is also dramatically altered (Kaufmann et al., 2002 Table 5 for primers Figure 1 Alternative splicing of Locus 210 in BASD. Alternative splicing variants are displayed in bar-link graph form. The bar length is proportional to its corresponding exon length. The 5 0 /3 0 end extension is indicated at the head of the graphic variant. EST accession numbers and cDNA library sources ('-' stands for unknown tissue types) are presented under each variant. EST counts in normal and cancer tissues and the statistical values (P) are displayed beside each cancer type. Exon location on the genomic contig is shown by paired numbers in brackets. In this case, variants 2 and 3 could not be put together because there is no EST in dbEST overlapping all alternative splicing sites of these two variants 10581) contains a variant with significance, but not when Bonferroni-corrected, which has 22 and seven ESTs in prostate and cancer (P ¼ 0.01). One variant of semenogelin II (SEMG2, Locus: 6407) gives an example of being significant even after Bonferroni correction, which has EST numbers of 94 and 0 in prostate and cancer tissues (Po1eÀ6).
To verify the statistical prediction, RT-PCR was applied to measure the expression level of nine genes selected from hepatocellular carcinoma (HCC) and lung cancer. In the four normal and tumor tissue pairs of HCC and six pairs of lung cancer examined, eight of the nine genes' expressions were consistent with our prediction (Figure 3) . In addition, genes related to HCC carcinogenesis from cDNA array were further used to check our data. Those variants that cover the gene sequences represented on the array membrane were chosen and their prediction data were combined. Of the 26 genes with an altered expression level from the array data, 25 genes were present in both BASD and array. Two genes did not have the same prediction data as the array data, and 10 genes did not give prediction of statistical significance, owing to limited ESTs. The predicted expression levels of the remaining 13 genes (52%) were consistent with the array data. This result indicates that the prediction of cancerassociated splicing variants was reliable if there were enough ESTs.
A total of 2149 variants (about 8% of all 26 812 splicing variants) from 1827 genes were found to have different EST counts between cancer and normal tissues with a statistical significance of 0.05 (Table 4) . After Bonferroni correction, there are only 383 variants that have statistical significance (Table 4 ). This small group of variants will have a relatively higher confidence of cancer relationship. The statistics of P-value distribution of the cancer-associated variants are illustrated in Figure 4 . No significant difference was observed between the P-value distribution of the cancer-associated and normal tissue-associated variants. As shown in the EST number distribution (Figure 2 ), the peak of the distribution of cancer-related variants shifted to the right compared with the overall EST number distribution. About 85% cancer-related variants had more than 16 ESTs. Based on the statistics of the 127 genes sample, the frequencies of cancer-specific variants varied from 3 The total number is smaller than the sum of this column because some alternative splice variants are counted in multiple tissues (Nash et al., 2002) . Our result increases the necessity to study decorin's impact in other cancers. Catechol-O-methyltransferase (COMT, Locus: 1312) catalyses the methylation of catecholamines and plays a role in melanogenesis. Low-activity COMT allele was significantly related to regional lymph node metastasis of breast cancer (Matsui et al., 2000) . From our database, variant 6 of this gene, which has an alternative 5 0 untranslated region, is significantly overexpressed in skin cancer tissue, while no difference was predicted for other variants. Our data also imply that different variants from the same gene may be associated with different cancers. Although both variants 1 and 2 of decorin were underexpressed in lung and placenta cancers, downregulation in breast cancer and HCC was only demonstrated in variant 1. Multiple alternative splicing variants are known for this gene; however, no study has been carried out on the relationship between different decorin variants and different cancers. The disabled homolog 2 (DAB2, Locus: 1601) gene is another example. DAB2 exhibits a negative control for cell growth and survival. The re-expression of DAB2 in breast cancer cells leads to the suppression of c-fos expression and cell growth inhibition (He et al., 2001) . Variant 1 of DAB2 is downregulated in most cancers including breast cancer, lung cancer, nervous cancer and placenta cancer, whereas decreased expression of DAB2 variant 8, partial deletion in exon 9 of variant 1, was only detected in liver tissue.
Discussion
We constructed BASD to search for splicing variants of gene transcripts, especially those associated with cancer. A higher percentage of alternative splicing (81%) than the reported ratio of 30-65% (Mironov et al., 1999; Brett et al., 2000; Kan et al., 2002) is suggested. This is mainly due to the inclusion of EST singletons in the BASD, since 58% of splicing variants are supported by one EST in our database. When the EST singletons are excluded from BASD, the percentage of genes with alternative splicing sites becomes comparable (66%) to the percentage in the previous reports. Splicing variants represented by singleton EST were sometimes considered noninformative (Mironov et al., 1999; Brett et al., 2000) , since the singleton ESTs may introduce nonnative splicing events. However, we retained these variants because six of eight single-EST-supported variants (75%) were confirmed by RT-PCR in our study (Table 2) , demonstrating the value of these single-EST-supported variants in mining genomic information. A recent publication by Wang et al. also described screening for cancer-related alternative splicing using RefSeq alignment. Wang et al. searched 11 014 genes and identified 26 258 alternative splicing variants, of which 845 are cancer related; whereas we searched 4322 genes and identified 26 812 splicing variants, of which 2149 are associated with cancer. The possible reasons for the difference might include: first, the statistic tool Wang et al. used is a Z-test, which assumes that the frequency of alternative splicing variants is a normal distribution, while we used Fisher's exact test, a nonparametric method; second, we included genomic sequence in the alignment, and thus have a better chance to identify the alternative splicing events located in the untranslated regions; third, the E-value and gap length for BLAST in our study are 1eÀ30 and 7 base pairs (bp), whereas those applied by Wang et al. are 1eÀ10 and 10 bp. In Wang et al.'s dataset of 845 cancer-related genes, 224 genes overlapped with the 4322 genes included in our database, and 174 (78%) genes were also identified as cancer-associated variants as per our prediction. Although we are unable to compare the complete gene lists studied in the two reports, it seems very likely that the two databases have a different coverage of the RefSeq.
We started from 17 448 reference sequences while others used UniGene, which contains about 104 170 human clusters. One advantage of RefSeq is that a permanent sequence ID was used to represent a gene in RefSeq, while the UniGene number might be changed or retired from time to time (Schuler 1997; Pruitt and Maglott, 2001 ). This feature of RefSeq makes it very easy to compare the results of different batches. Another benefit of RefSeq is that it avoids self-assembly of ESTs in the UniGene, which may cause misclassification in some alternative splicing cases. A survey using 254 variants from 34 randomly chosen genes showed that about 10% of variants were assigned to irrelevant UniGene clusters (data not shown). For example, using ASA, ESTs AI741905 and AI436103 were grouped to gene chimaerin 1 (CHN1) as a splicing variant because these two ESTs contain part of exon 6 and the entire exon 7 of CHN1 and are located at the same chromosome site. However, in the UniGene database, these ESTs were separated from the CHN1 cluster (Hs.380138) as an independent cluster, Hs.369565. However, since the RefSeq does not include all human genes, it is possible that an EST cluster were considered as a splicing variant to a homologous ResSeq, although it has a better homology to another gene that is not yet listed by RefSeq. This kind of error would be reduced with the accumulation of additional genomic data and increased RefSeq database size.
Our work presents a genomic view of the relationship between cancer and alternative splicing. We observed that about one-third of alternative splicing variants were only detected in cancer tissues. Although no clear explanations exist until now, increasing of alternative splicing was well documented. Alterative splicing in DNA polymerase beta appears much more often in bladder cancer tissues and cell lines than in normal bladder tissue, although it does occur in normal bladder tissue (Thompson et al., 2002) . Kaufmann et al. (2002) studied the alternative transcripts of neurofibromatosis type 1 (NF1) in three tumor tissues and found that the types of spliced variants were about twice more than in normal tissues . In addition, physiological condition, temperature and PH value, which are often altered in tumor cells, would increase aberrant variants of NF1 in vitro (Ars et al., 2000; Kaufmann et al., 2002) . Enhancement of alternative splicing in cancer cells may have a similar significant impact on carcinogenesis as expression level change.
One implication of this study could be that different variants might play different roles in carcinogenesis. The expression of AIPL1, the fourth causative gene of Leber congenital amaurosis, is specific to human retina and cell lines of retinal origin (van der Spuy et al., 2002) . Among the five AIPL1 variants predicted in BASD, only the expression of variant 1 is increased to nearly 10-folds in retinoblastoma and may be a candidate tumor marker. Increased expression of fibroblast growth factors (FGFs) is observed in a substantial fraction of human prostate cancers and cell lines. Valve et al. (2001) reported that isoforms a and e of FGF-8 were overexpressed at significantly higher frequencies in prostate cancer, while isoform b remained at similar levels in prostate cancer and in control prostates. Our data also showed that only one variant of FGF5 was significantly more counted in prostate cancer. These data implied that only a fraction of isoforms of FGFs might be related to the genesis of prostate cancer. Shifting of the splicing pattern might cause the dominant-negative or constitutively activated form of the wild-type protein that contributes to or results from carcinogenesis. From our analysis of HCC-related variants, alteration of amino-acid sequences was found in about 27% variants (data not shown). The study of altered gene expression levels might thus be specific to splicing isoforms in cancer research, as our recent work showed only isoform B of SVH to be involved in HCC carcinogenesis (Huang et al., 2003) .
Owing to the limited number of ESTs for low-abundant transcripts, and due to ESTs that could not completely cover some of the long transcripts, a number of alternative splicing variants might still be underestimated. The statistical significance of the association between splicing variants and cancers may also be affected, as identified in Table 4 (bladder, esophagus, and thymus cancers). The distribution of EST numbers also suggests that cancer-related variants usually include more ESTs (Figure 2 ). In addition, the predicted cancer-associated splicing variants may also be affected, for cancer tissues may be composed of a mixture of cell types differing from the normal tissue counterparts, and the fact that mRNA variants associated with rare cancer type may not be identified due to an insufficient number of cDNA libraries. Despite this, EST-genomic DNA alignment can still provide a helpful approach to identify cancer-specific splicing variants. Proper mining of this database may contribute in cancer studies.
Materials and methods
Data source
The analysis employed the human EST database and human genome database from the NCBI. Sequences in the RefSeq were used as the standard to create database (BASD). The LocusLink database was used to identify the genomic location of reference sequences in RefSeq. 
Locate reference sequences and ESTs to genome sequences
Genes were located to the genomic contig according to the LocusLink database, thus multi-copy genes and pseudogenes might not interfere during the BLAST process (Pruitt and Maglott, 2001 ). The reference sequence of each gene was used as the standard and BLASTed against the human EST database with match/mismatch scores of 1/À3 and E-value of 1eÀ30. If there were more than one sequence under a reference sequence record, the first one was selected as the standard for analysis. Homolog EST sequences from the human EST database and other sequences under the same reference sequence record were taken out and pooled together as homolog sequences. All these homolog sequences tended to locate to the same genomic region as the reference sequence.
Construction of ASA and discovery of putative exons and alternative splicing variants Reference sequences were BLASTed against the mapped genomic contigs. Repeat sequences were masked by RepeatMasker (Smit, AFA and Green P RepeatMasker at http://ftp.genome.washington.edu/RM/RepeatMasker.html). Putative exons were determined by using bl2seq with default scoring values, except match/mismatch scores of 1/À2, word size of 7, cutoff score of 7 and expect value of 10 guaranteeing the identification of short exons (at least 7 bp) and sufficient BLAST stringency. The whole reference sequence should spread along the contig along the same direction of BLAST hits, and mismatched sequences among neighboring exons should be less than 13 bp. Reference sequences not passing these criteria were discarded. The ends of putative exons are trimmed or elongated to find canonical splice sites (GT/AG and GC/AG). After determination of the putative exons, each exon was BLASTed against the pooled homolog ESTs (threshold 1eÀ30). The exon-EST relationships were coded in the format of (query start, query end, subject start, subject end). A relationship is determined as connective if any two matched exons in an EST were in the same direction and the sequences along the contig and mismatched parts of adjacent ends were shorter than 13 bp. The longest relationship pathway thus could be found according to the connective relationship. If an EST contained sequences that could not be aligned to previously determined exons, it would once again be aligned to the transcription strand of genomic contig additionally. A new relationship would be accepted if the genomic location of this sequence part was determined as connective with context exons. If a new connective relationship was introduced at the 5 0 or 3 0 end of EST, there should be at least 20 bp homology to the genomic sequences. If the 5 0 and 3 0 end of an EST could not be aligned to the genomic sequence and the unaligned end was shorter than 50 bp, this unaligned sequence part would be deleted from the EST to avoid possible sequencing errors. If an internal part of an EST could not align to the genomic sequence, this EST was taken as an unqualified sequence and removed. The splicing site would be found through the one-to-one mapping of the relationship pathways.
Comparing the ESTs of homolog with the query sequence would produce a connective matrix. Any ESTs that have the same connective pathway were put into one cluster, representing a unique alternative splicing variant. Two independent EST clusters would not be grouped together, unless there was an EST covering both clusters' alternative spliced sites.
Construction of BASD
Initiated from reference sequences, hypothetical alternative splicing variants were identified by ASA and deposited into BASD. Each variant from the same gene transcript was named numerically beginning with the Locus ID of this gene. Splicing variants were presented in graphic format according to the alignment position in genomic sequences. Exons were represented by bars proportional to their sequence length. Text description was attached under the graph. The GenBank accession numbers of ESTs and cDNA library names were labeled. Under each splicing variant, the exon location on the genome contig was given in bracketed base pair numbers. Key words, such as Locus ID and gene name, could be used to retrieve the database through http://humgene.biosino.cn/ BASD.html.
Identification of alternative splicing variants related to cancer tissues
From the UniLib, we retrieved the tissue source of each library. In order to prevent inconsistence in the classification of tissue types in UniLib, all tissue information of cDNA libraries was checked manually. Libraries from the same tissue type were grouped together. Libraries containing pooled tissues or without clearly described tissue sources were not grouped to any tissue types. In all, 220 libraries indicated as 'subtracted' or 'normalized' were not included in order to avoid deviation in tissue distribution analysis. Libraries from cancer and its counterpart normal tissues were paired for comparing. After the splicing variants were determined, the EST numbers of each variant in cancer (IC) or normal (IN) tissue were counted according to their source cDNA library. The total library EST numbers were calculated by adding all ESTs from the same kind of cancer (TC) or normal (TN) tissues. Fisher's exact test was applied to check if the difference of EST counts between cancer tissues and normal counterparts (IC and IN) was statistically significant compared with the total library EST numbers (TC and TN) (Po0.05) (Scheurle et al., 2000; Baranova et al., 2001) . In order to reduce the possible false positives caused by simultaneously performed multiple comparison, Bonferroni correction (a 0 ¼ 0.05/16945) was further applied to Fisher's exact test.
RT-PCR and clinical samples
Clinical cancer samples were provided by Zhongshan Hospital. Each sample pair consisted of cancer and normal tissues from the same patient. Histological examination was carried out in the Department of Pathology, Zhongshan Hospital. Total RNA was extracted by Trizol and quantified by 18S RNA. RT was performed using M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) with oligo-dT (Sangon, Shanghai, China) as primer following the manufacturer's instruction.
PCR primers specific for the splicing variants were designed by PrimerSelect (DNAStar, Madison, WI, USA) and are shown in Table 5 . Briefly, for exon extension and insertion, one of the PCR primers was designed in that additional region; for exon deletion and shortened exon, PCR primer was selected at the splicing site covering the deleted region. Amplification was performed using LA Taq (Takara Bio, Dalian, Liaoning, China) for 40 s at 941C, 40 s at 56-621C, 60 s at 721C for 19-26 cycles. b-Actin mRNA was chosen as the internal control, and a cycle gradation test was carried out to determine the optimal conditions. Each sample was amplified in duplication. PCR products were purified and sequenced to confirm the amplified variants.
